(Q35684102)

9 August 2017

1 reference

title

Palliative treatment for advanced non-small cell lung cancer (English)

1 reference

9 August 2017

Fergus Macbeth

1

1 reference

9 August 2017

Richard Stephens

series ordinal

2

1 reference

9 August 2017

publication date

1 February 2004

1 reference

Hematology / Oncology Clinics of North America

9 August 2017

published in

1 reference

9 August 2017

volume

18

1 reference

9 August 2017

issue

1

1 reference

9 August 2017

page(s)

115-130

1 reference

Evaluating the quality of life of cancer patients: assessments by patients, significant others, physicians and nurses

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900140-0

7 January 2021

Observer error in grading performance status in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900140-0

7 January 2021

Prognostic value of performance status assessed by patients themselves, nurses, and oncologists in advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900140-0

7 January 2021

Preferences for chemotherapy in patients with advanced non-small cell lung cancer: descriptive study based on scripted interviews

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900140-0

7 January 2021

Effects of Vinorelbine on Quality of Life and Survival of Elderly Patients With Advanced Non-Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900140-0

7 January 2021

Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900140-0

7 January 2021

Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900140-0

7 January 2021

Do all patients with advanced non-small-cell lung cancer benefit from cisplatin-based combination therapy?

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900140-0

7 January 2021

The benefits of chemotherapy in patient subgroups with unresectable non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900140-0

7 January 2021

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900140-0

7 January 2021

Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: a Phase II trial in patients with metastatic nonsmall cell lung carcinoma .

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900140-0

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900140-0

7 January 2021

GLOB-1: a prospective randomised clinical phase III trial comparing vinorelbine-cisplatin with vinorelbine-ifosfamide-cisplatin in metastatic non-small-cell lung cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900140-0

7 January 2021

Symptoms at presentation for treatment in patients with lung cancer: implications for the evaluation of palliative treatment. The Medical Research Council (MRC) Lung Cancer Working Party

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900140-0

7 January 2021

Randomized trial of palliative two-fraction versus more intensive 13-fraction radiotherapy for patients with inoperable non-small cell lung cancer and good performance status. Medical Research Council Lung Cancer Working Party.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900140-0

7 January 2021

Defining and analysing symptom palliation in cancer clinical trials: a deceptively difficult exercise

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900140-0

7 January 2021

Palliation of symptoms in non-small cell lung cancer: a study by the Yorkshire Regional Cancer Organisation Thoracic Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900140-0

7 January 2021

Influence of cisplatin-use, age, performance status and duration of chemotherapy on symptom control in advanced non-small cell lung cancer: detailed symptom analysis of a randomised study comparing cisplatin-vindesine to gemcitabine

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900140-0

7 January 2021

Counting the costs of chemotherapy in a National Cancer Institute of Canada randomized trial in nonsmall-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900140-0

7 January 2021

Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900140-0

7 January 2021

A longitudinal study of quality of life in advanced non-small cell lung cancer: Cancer and Leukemia Group B (CALGB) 8931.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900140-0

7 January 2021

Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer--a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-Small Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900140-0

7 January 2021

Decision framework for chemotherapeutic interventions for metastatic non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900140-0

7 January 2021

The cost-effectiveness of navelbine alone or in combination with cisplatin in comparison to other chemotherapy regimens and best supportive care in stage IV non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900140-0

7 January 2021

Treatment strategies in advanced and metastatic cancer: differences in attitude between the USA, Canada and Europe

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900140-0

7 January 2021

Palliative radiation for stage 3 non-small cell lung cancer--a prospective study of two moderately high dose regimens

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900140-0

7 January 2021

Inoperable non-small-cell lung cancer (NSCLC): a Medical Research Council randomised trial of palliative radiotherapy with two fractions or ten fractions

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900140-0

7 January 2021

A Medical Research Council (MRC) randomised trial of palliative radiotherapy with two fractions or a single fraction in patients with inoperable non-small-cell lung cancer (NSCLC) and poor performance status. Medical Research Council Lung Cancer Wor

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900140-0

7 January 2021

Randomized phase III trial of single versus fractionated thoracic radiation in the palliation of patients with lung cancer (NCIC CTG SC.15).

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900140-0

7 January 2021

A palliative accelerated irradiation regimen for advanced non-small-cell lung cancer vs. conventionally fractionated 60 GY: results of a randomized equivalence study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900140-0

7 January 2021

Palliative radiotherapy for lung cancer: two versus five fractions

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900140-0

7 January 2021

[Radiotherapy for stage III, inoperable, asymptomatic small cell lung cancer. Final results of a prospective randomized study (240 patients)]

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900140-0

7 January 2021

Palliative radiotherapy for inoperable carcinoma of the lung: final report of a RTOG multi-institutional trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900140-0

7 January 2021

A randomized study on palliative radiation therapy for inoperable non small cell carcinoma of the lung

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900140-0

7 January 2021

Radiation myelopathy: estimates of risk in 1048 patients in three randomized trials of palliative radiotherapy for non-small cell lung cancer. The Medical Research Council Lung Cancer Working Party.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900140-0

7 January 2021

A case of radiation myelopathy after 2 x 8.5 Gy for inoperable non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900140-0

7 January 2021

Hypofractionated irradiation for inoperable non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900140-0

7 January 2021

Short-course palliative radiotherapy in non-small-cell lung cancer: results of a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900140-0

7 January 2021

Immediate versus delayed palliative thoracic radiotherapy in patients with unresectable locally advanced non-small cell lung cancer and minimal thoracic symptoms: randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900140-0

7 January 2021

10.1016/S0889-8588(03)00140-0

Identifiers

DOI

1 reference

9 August 2017

1 reference